Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2593418 | 0.98 | KDM4E (0.45) | KDM4EMAPTUSP2ESR1ESR2 | |
| SCHEMBL29054940 | 0.88 | KDM4E (0.47) | KDM4EMAPTALDH1A1KMT2ALMNA | |
| SCHEMBL29054905 | 0.88 | KDM4E (0.47) | KDM4EMAPTALDH1A1KMT2ALMNA | |
| SCHEMBL7799885 | 0.82 | ESR1 (0.39) | ESR1ESR2PKMKMT2ALMNA | |
| SCHEMBL29054910 | 0.78 | KDM4E (0.46) | KDM4EALDH1A1KMT2ACYP3A4TSHR | |
| SCHEMBL1388961 | 0.77 | CA1 (0.43) | KDM4EUSP2ESR1ESR2ALDH1A1 | |
| SCHEMBL3119668 | 0.77 | TSHR (0.42) | KDM4EUSP2ESR1ESR2ALDH1A1 | |
| SCHEMBL18954349 | 0.77 | KDM4E (0.44) | KDM4EMAPTUSP2PDK1PDK2 | |
| SCHEMBL12139803 | 0.76 | KDM4E (0.46) | KDM4EMAPTUSP2ALDH1A1PKM | |
| SCHEMBL4589973 | 0.76 | KDM4E (0.42) | KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016115013-A1 | CINNOLINE DERIVATIVES USEFUL AS CB-1 RECEPTOR INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-21 | — | — | WO | claimed |
| EP-3044210-A2 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | Cortendo AB (publ) (US) | 2016-07-20 | — | — | EP | claimed |
| EP-0910415-B1 | FLUORO-LABELLED ANTHRACYCLINE AND ANTHRACYCLINONE DERIVATIVES | PHARMACIA ITALIA SPA (IT) | 2004-05-12 | — | — | EP | claimed |
| JP-2000514784-A | — | — | 2000-11-07 | — | — | JP | claimed |
| US-6103700-A | FOR DIAGNOSING AMYLOIDOSIS | PHARMACIA & UPJOHN S.P.A. (IT) | 2000-08-15 | — | — | US | claimed |
| EP-0910415-A1 | FLUORO LABELLED ANTHRACYCLINONE AND ANTHRACYCLINE DERIVATIVES | PHARMACIA & UPJOHN S.p.A. (IT) | 1999-04-28 | — | — | EP | claimed |
| WO-1997049433-A1 | FLUORO LABELLED ANTHRACYCLINONE AND ANTHRACYCLINE DERIVATIVES | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-12-31 | — | — | WO | claimed |
| US-20250145628-A1 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NOVO NORDISK A/S (DK) | 2025-05-08 | — | — | US | disclosed |
| CN-119301126-A | Pyrazolopyrimidine compound, composition containing pyrazolopyrimidine compound and application of pyrazolopyrimidine compound | 诺和诺德股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-4479402-A1 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Novo Nordisk A/S (DK) | 2024-12-25 | — | — | EP | disclosed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-115403568-B | Quinazoline Aurora A covalent inhibitor and preparation method and application thereof | 中山大学 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023155004-A1 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | INVERSAGO PHARMA INC. (CA) | 2023-08-24 | — | — | WO | disclosed |
| US-20080188484-A1 | INDOL-2-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
| WO-2007127175-A2 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-08 | — | — | WO | disclosed |
| EP-0910415-B1 | FLUORO-LABELLED ANTHRACYCLINE AND ANTHRACYCLINONE DERIVATIVES | PHARMACIA ITALIA SPA (IT) | 2004-05-12 | — | — | EP | disclosed |
| US-6103700-A | FOR DIAGNOSING AMYLOIDOSIS | PHARMACIA & UPJOHN S.P.A. (IT) | 2000-08-15 | — | — | US | disclosed |
| EP-0910415-A1 | FLUORO LABELLED ANTHRACYCLINONE AND ANTHRACYCLINE DERIVATIVES | PHARMACIA & UPJOHN S.p.A. (IT) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997049433-A1 | FLUORO LABELLED ANTHRACYCLINONE AND ANTHRACYCLINE DERIVATIVES | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145628-A1 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | CNR1, CNR2, TRPV1 | KDM4E 2777/4885MAPT 74/4885USP2 4098/4885 |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIK3CA, PIK3CD, PIK3CB | KDM4E 529/4885MAPT 1800/4885USP2 2121/4885 |
| US-20080188484-A1 | INDOL-2-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HRH4, HRH3, HRH2 | KDM4E 852/4885MAPT 2077/4885USP2 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.